AMO Pharma Limited

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	Arrhythmias, Cardiac, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Death, Sudden, Death, Sudden, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arrhythmogenic right ventricular cardiomyopathy, cardiac arrest, cardiomyopathy, cardiovascular disorder, congenital heart disease, heart disorder	Recruiting	Phase 2	2026-03-12		NCT06174220
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Disorders, Atrophic, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease	Recruiting	Phase 2 / Phase 3	2025-05-28		NCT05004129

Clinical trials